Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Gets A Boost From Shingrix And Other New Drugs

Executive Summary

The shingles vaccine Shingrix and new HIV and respiratory drugs drove first quarter growth at GlaxoSmithKline, even as Advair and Breo sales were impacted by a generic.

You may also be interested in...



10 Triumphant Drug Launches Of The Decade

The view from 2020: Scrip looks back at the most successful commercial launches of the decade.

ViiV's Dovato Could Challenge Status Quo In Naive EU HIV Patients

The approval of ViiV’s new once-daily, two-drug single-pill for HIV/AIDS could lead to a tough battle in Europe with established therapies.

  

ViiV's Dovato: Treatment-Naive HIV Is Earmarked For The "Complete Regimen"

The first approval in the US of a once-daily single-tablet, two-drug regimen for treatment-naive HIV from the HIV/AIDS therapy specialist, ViiV Healthcare, suggests a shift away from three-drug regimens for HIV/AIDS could be gathering pace.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125156

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel